BCL2 and lymphoma: One month later, when lymphoma had progressed and abdominal pain had reappeared, on day +75 (July 16, 2019), a primary tumor-derived clone with TP53 missense mutation, KMT2D truncating mutation, and IGLL5 missense mutation reamplified rapidly, and a new subclone with BCL2 and DDX3X mutations emerged.